BACKGROUND: To understand the molecular and morphological alterations in the tight junction in colorectal cancer (CRC) tissues, the expression of eight tight junction proteins in normal and cancer colorectal tissues were compared. PATIENTS AND METHODS: Adenocarcinoma tissues and paired normal mucosa were resected from surgical specimens of CRC patients. The expression of occludin, ZO-1, ZO-2, and claudin-1 -5 was analyzed at the mRNA level by quantitative reverse transcription-polymerase chain reaction (RT-PCR) and at the protein level by immunohistochemistry. RESULTS: The expression of claudin-1 and claudin-2 in cancer tissues was upregulated 40- and 49.2-fold, respectively, at the mRNA level, as compared with that in normal tissues. The up-regulation of these two claudins was also observed at the protein level and it appeared to depend on the depth of tumor invasion. CONCLUSION: Claudin-1 and claudin-2 were found to be overexpressed in CRC tissues. They may be useful as tumor markers and targets for the treatment of colorectal cancer.
BACKGROUND: To understand the molecular and morphological alterations in the tight junction in colorectal cancer (CRC) tissues, the expression of eight tight junction proteins in normal and cancer colorectal tissues were compared. PATIENTS AND METHODS: Adenocarcinoma tissues and paired normal mucosa were resected from surgical specimens of CRC patients. The expression of occludin, ZO-1, ZO-2, and claudin-1 -5 was analyzed at the mRNA level by quantitative reverse transcription-polymerase chain reaction (RT-PCR) and at the protein level by immunohistochemistry. RESULTS: The expression of claudin-1 and claudin-2 in cancer tissues was upregulated 40- and 49.2-fold, respectively, at the mRNA level, as compared with that in normal tissues. The up-regulation of these two claudins was also observed at the protein level and it appeared to depend on the depth of tumor invasion. CONCLUSION:Claudin-1 and claudin-2 were found to be overexpressed in CRC tissues. They may be useful as tumor markers and targets for the treatment of colorectal cancer.
Authors: Jochen Gaedcke; Marian Grade; Klaus Jung; Jordi Camps; Peter Jo; Georg Emons; Anastasia Gehoff; Ulrich Sax; Markus Schirmer; Heinz Becker; Tim Beissbarth; Thomas Ried; B Michael Ghadimi Journal: Genes Chromosomes Cancer Date: 2010-11 Impact factor: 5.006
Authors: Sébastien Tabariès; Fanny Dupuy; Zhifeng Dong; Anie Monast; Matthew G Annis; Jonathan Spicer; Lorenzo E Ferri; Atilla Omeroglu; Mark Basik; Eitan Amir; Mark Clemons; Peter M Siegel Journal: Mol Cell Biol Date: 2012-05-29 Impact factor: 4.272
Authors: Yoshito Tomimaru; Hironori Koga; Hirohisa Yano; Suzanne de la Monte; Jack R Wands; Miran Kim Journal: Liver Int Date: 2013-05-08 Impact factor: 5.828
Authors: Eszter Székely; Péter Törzsök; Péter Riesz; Anna Korompay; Attila Fintha; Tamás Székely; Gábor Lotz; Péter Nyirády; Imre Romics; József Tímár; Zsuzsa Schaff; András Kiss Journal: J Histochem Cytochem Date: 2011-08-10 Impact factor: 2.479
Authors: Ágnes Holczbauer; Benedek Gyöngyösi; Gábor Lotz; Attila Szijártó; Péter Kupcsulik; Zsuzsa Schaff; András Kiss Journal: J Histochem Cytochem Date: 2013-02-05 Impact factor: 2.479